CHRNA7 and rheumatoid arthritis: Due to the obvious limitations of the therapeutic value of nicotine, as a result of its pharmacological nonspecificity and toxic side effects, selective α7nAChR agonists may be more favorable candidates for development as a novel medication for the treatment of RA.